-
Genomic Profiling Identifies Patients Most Likely to Respond to Immunotherapy
New discoveries and ongoing research continue to confirm the powerful therapeutic implications of precision medicine for cancer patients. The recent FDA approval of pembrolizumab for patients whose cancers have a specific biomarker is no exception.
Category: News
-
Tumor Mutations: The Upside?
A team of investigators led by researchers at Georgetown Lombardi Comprehensive Cancer Center has found that the tumor mutation load (TML) in a patient’s cancer biopsy varied by age and the type of cancer, along with several other factors. The findings include 14 types of solid tumors and over 8,000 tissue samples, offering one of the most comprehensive analyses of TML to date.
Category: News
-
Deficiencies in DNA Repairing Identified in Tumors
The DNA repair deficiency, called homologous recombination deficiency, or HRD, has previously been studied in only a few cancers, but as researchers at Georgetown Lombardi Comprehensive Cancer Center report, HRD can be found in all of the cancer types the researchers studied, including prostate, breast, pancreatic, and endometrial cancers as well as two of the more deadly types: ovarian cancer and glioma, a type of brain cancer.
Category: News
-
Ultra-personal therapy: Gene tumor boards guide cancer care
Doctors were just guessing a decade ago when they gave Alison Cairnes’ husband a new drug they hoped would shrink his lung tumors. Now she takes it too, but the choice was no guesswork. Sophisticated gene tests suggested it would fight her gastric cancer, and they were right.
Category: News
-
Time to Change the Way We Price Drugs: Value-based pricing, technology assessment among possible solutions
The U.S. should develop a different system of pricing drugs, Peter Bach, MD, said at a forum in Washington, DC on high prescription drug prices hosted by The Atlantic.
Category: News
-
The State of Cancer Research – Moving from Bench to Bedside Faster
John Marshall, MD – Director, The Ruesch Center for the Cure of GI Cancers Lou Weiner, MD – Director, Lombardi Comprehensive Cancer Center
Category: Policy Briefing
-
Moonshot 2.0 – How We Continue to Build on the Progress of Public-Private Initiatives in 2017
John Marshall, MD, Director, Ruesch Center for the Cure of GI Cancers M. Gregg Bloche, MD, JD, Professor of Law, Georgetown University Law Center Neel Sukhatme, PhD, Associate Professor of Law, Georgetown University Law Center
Category: Policy Briefing
-
Challenges to Patient Access – Paying for Cancer Care
Michael Sapienza, CEO, Colon Cancer Alliance Randy Burkholder, Vice President of Policy and Research, PhRMA Emily Pomeranz, GI Cancer Patient Dana Wollins, Senior Director, ASCO
Category: Policy Briefing
-
Cancer Research; 2017 Policy Directions
John Marshall, MD, Director, The Ruesch Center for the Cure of GI Cancer Governor Howard Dean, MD, Senior Advisor, Public Policy and Regulation, Dentons Law
Category: Policy Briefing
-
Young Adults Face Steep Increase of Colorectal Cancer Risk
New study shows increased risk of colorectal cancer among young adults as risk among older adults declines.
Category: News